ArticlePloS one2026
Epidemiological characteristics of amebiasis in Japan from 2001 to 2022.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amebiasis cases in Japan are reported to the government according to the Infectious Diseases Control Law. Previous studies have shown significant reductions in total case numbers after 2018 and during the COVID-19 pandemic. This study aimed to clarify the recent trends of amebiasis cases in Japan, including during the pandemic period, with details on places of infection, using government surveillance data from January 1, 2001, to December 31, 2022. Change of time trends were modeled through piecewise mixed-effect regression model with knots set at 2018 and 2020. Year-to-year differences in case numbers were statistically assessed using Poisson regression model. And descriptive analyses of amebiasis cases reported in Japan by sex, age class, and prefecture (from 2001 to 2022) were conducted. Piecewise time trends of male-domestic cases showed increasing trend by 59.5 cases per year (p < 0.0001) before 2008. The trend slowed but still increased during 2008-2018, showing annual increase of 15.2 cases per year (p = 0.0014). A sharp decline occurred during 2018-2020, with cases decreasing by 219.0 cases per year (p < 0.0001). After 2020, the trend did not show statistically significant change (-16.9 cases per year, p = 0.6532). Poisson regression confirmed significant reductions in total and domestic cases between 2017-2018 and 2019-2020, while imported cases declined significantly only between 2019 and 2020. Male cases predominated, with most male cases in their 40s and 50s. Most cases of amebiasis have been reported in metropolitan areas. These results suggest that the decreased case numbers during the COVID-19 pandemic were due to not only the travel ban, but less socioeconomic activity. Furthermore, the epidemiology of amebiasis is similar to that of HIV infection in Japan, but the case numbers of amebiasis have not yet increased through 2022, showing a different trend from HIV infection and syphilis, the reason of which is unclear and needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.